Apalutamide Study Prioritized For Non-Metastatic Canstrate-Resistant Prostate Cancer
Men with non-metastatic castrate-resistant prostate cancer will soon know whether or not apalutamide is helpful. The USA based Food and Drug Administration has cut the review time from ten to six months. We might hear the FDA's ruling as early as April, 2018. Apalutamide (ARN-509) is an androgen receptor inhibitor and might prove to [...]
